Previous close | 0.0315 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | -0.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BAGNEUX, France, January 24, 2023--Regulatory News: Genomic Vision (Paris:GV) (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announces the appointment of Frederic Hammel as Chief Operating Officer, further strengthening its leadership team.
GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision announces successful beta testing of FiberSmart® FiberSmart® is Genomic Vision’s Artificial Intelligence (AI) powered and fully integrated software automating genomic analysisFiberSmart® leverages cutting-edge AI to rapidly analyze DNA replication kinetics and provide a seamless user experienceFiberSmart platform was successfully tested by AstraZeneca and the Fritz Lipmann Institute Bagneux (France), 5 January 2023 - Genomic Vision (FR00
GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer® Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a